Use of Mammalian Liver Cells for Artificial Liver Support

Advances in orthotopic liver transplantation have improved the survival rate of both acute and chronic liver failure patients to nearly 70%. However, the success of this treatment modality has created an international organ shortage. Many patients die while awaiting transplantation in part due to th...

Full description

Bibliographic Details
Main Authors: Hugo O. Jauregui M.D., Ph.D., Namita Roy Chowdhury, Jayanta Roy Chowdhury
Format: Article
Language:English
Published: SAGE Publishing 1996-05-01
Series:Cell Transplantation
Online Access:https://doi.org/10.1177/096368979600500302
id doaj-ac09c2f24ac4473ab8051c62e4d1d1b4
record_format Article
spelling doaj-ac09c2f24ac4473ab8051c62e4d1d1b42020-11-25T03:15:10ZengSAGE PublishingCell Transplantation0963-68971555-38921996-05-01510.1177/096368979600500302Use of Mammalian Liver Cells for Artificial Liver SupportHugo O. Jauregui M.D., Ph.D.0Namita Roy Chowdhury1Jayanta Roy Chowdhury2Department of Pathology and Laboratory Medicine, Division of Biology and Medicine, Brown University, Providence, RI 02906 USADepartment of Medicine and Molecular Genetics and the Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY 10461 USADepartment of Medicine and Molecular Genetics and the Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY 10461 USAAdvances in orthotopic liver transplantation have improved the survival rate of both acute and chronic liver failure patients to nearly 70%. However, the success of this treatment modality has created an international organ shortage. Many patients die while awaiting transplantation in part due to the minimal capacity to store viable transplantable livers beyond 24 h. Additionally, for many areas of the world, routine use of whole liver transplantation to treat liver disease is impractical due to the demands on both financial and technical resources. Potentially, these issues may be alleviated, at least in part, by the use of liver cell transplantation or cellular-based liver assist devices. The well-documented regenerative capacity of the liver may obviate the need for whole organ transplantation in some instances of acute failure, if the patient may be provided temporary metabolic support. Although other patients ultimately may require transplantation, a longer period of time to find a suitable organ for transplantation may be gained by that supportive therapy. The field of liver cell transplantation may offer solutions to patients with inherited metabolic deficiencies or chronic liver disease. The potential to treat an hepatic disorder by using only a fraction of the whole liver would increase the number of whole organs available for orthotopic liver transplantation. Research in the fields of hepatocyte based intra- and extra-corporeal liver support is providing evidence that these therapeutic modalities may ultimately become routine in the treatment of severe liver disease. A historic overview of that technology along with its current status is discussed.https://doi.org/10.1177/096368979600500302
collection DOAJ
language English
format Article
sources DOAJ
author Hugo O. Jauregui M.D., Ph.D.
Namita Roy Chowdhury
Jayanta Roy Chowdhury
spellingShingle Hugo O. Jauregui M.D., Ph.D.
Namita Roy Chowdhury
Jayanta Roy Chowdhury
Use of Mammalian Liver Cells for Artificial Liver Support
Cell Transplantation
author_facet Hugo O. Jauregui M.D., Ph.D.
Namita Roy Chowdhury
Jayanta Roy Chowdhury
author_sort Hugo O. Jauregui M.D., Ph.D.
title Use of Mammalian Liver Cells for Artificial Liver Support
title_short Use of Mammalian Liver Cells for Artificial Liver Support
title_full Use of Mammalian Liver Cells for Artificial Liver Support
title_fullStr Use of Mammalian Liver Cells for Artificial Liver Support
title_full_unstemmed Use of Mammalian Liver Cells for Artificial Liver Support
title_sort use of mammalian liver cells for artificial liver support
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 1996-05-01
description Advances in orthotopic liver transplantation have improved the survival rate of both acute and chronic liver failure patients to nearly 70%. However, the success of this treatment modality has created an international organ shortage. Many patients die while awaiting transplantation in part due to the minimal capacity to store viable transplantable livers beyond 24 h. Additionally, for many areas of the world, routine use of whole liver transplantation to treat liver disease is impractical due to the demands on both financial and technical resources. Potentially, these issues may be alleviated, at least in part, by the use of liver cell transplantation or cellular-based liver assist devices. The well-documented regenerative capacity of the liver may obviate the need for whole organ transplantation in some instances of acute failure, if the patient may be provided temporary metabolic support. Although other patients ultimately may require transplantation, a longer period of time to find a suitable organ for transplantation may be gained by that supportive therapy. The field of liver cell transplantation may offer solutions to patients with inherited metabolic deficiencies or chronic liver disease. The potential to treat an hepatic disorder by using only a fraction of the whole liver would increase the number of whole organs available for orthotopic liver transplantation. Research in the fields of hepatocyte based intra- and extra-corporeal liver support is providing evidence that these therapeutic modalities may ultimately become routine in the treatment of severe liver disease. A historic overview of that technology along with its current status is discussed.
url https://doi.org/10.1177/096368979600500302
work_keys_str_mv AT hugoojaureguimdphd useofmammalianlivercellsforartificialliversupport
AT namitaroychowdhury useofmammalianlivercellsforartificialliversupport
AT jayantaroychowdhury useofmammalianlivercellsforartificialliversupport
_version_ 1724640213033025536